Download this whitepaper to learn more.
Artificial intelligence (AI) is redefining the value chain as it plays a larger role in drug discovery. However, with AI technology now impacting everything from target identification to lead optimization, as well as preclinical development and even clinical trials, life sciences organizations face key business challenges due to the increased risk of significant tax implications.
Access our valuable resource to avoid missed opportunities for effective tax planning. Learn how to successfully unlock value and mitigate potential audit risks. We explore:
- How AI is reshaping drug discovery
- The impact of AI-aided R&D on tax structures
- Important transfer pricing considerations
- Why AI is creating a shift in value chains
- Actionable strategies and key partnerships to fully protect your business
- And more
Offered Free by: EY
See All Resources from: EY
